Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
Performance of three automated commercial serological IgG-based assays was investigated
for assessing SARS-CoV-2 “ever”(past or current) infection in a population-based sample in
a high exposure setting. PCR and serological testing was performed on 394 individuals.
SARS-CoV-2-IgG seroprevalence was 42.9%(95% CI 38.1–47.8%), 40.6%(95% CI 35.9–
45.5%), and 42.4%(95% CI 37.6–47.3%) using the CL-900i, VidasIII, and Elecsys assays,
respectively. Between the three assays, overall, positive, and negative percent agreements …
for assessing SARS-CoV-2 “ever”(past or current) infection in a population-based sample in
a high exposure setting. PCR and serological testing was performed on 394 individuals.
SARS-CoV-2-IgG seroprevalence was 42.9%(95% CI 38.1–47.8%), 40.6%(95% CI 35.9–
45.5%), and 42.4%(95% CI 37.6–47.3%) using the CL-900i, VidasIII, and Elecsys assays,
respectively. Between the three assays, overall, positive, and negative percent agreements …
以上显示的是最相近的搜索结果。 查看全部搜索结果